NEO: NeoGenomics, Inc.
About
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Current Value
$15.291 Year Return
Current Value
$15.291 Year Return
Key Details
Market Cap
$1.97B
P/E Ratio
-24.97
1Y Stock Return
-19.92%
1Y Revenue Growth
12.06%
Dividend Yield
0.00%
Price to Book
2.2
Strategies that include NEO
Stock's related to NEO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LGIH | 50.78% | $2.38B | -15.32% | 0.00% |
| FLGT | 48.77% | $519.98M | -37.82% | 0.00% |
| ARI | 45.97% | $1.27B | -14.15% | 14.16% |
| MATW | 45.55% | $731.28M | -31.68% | 4.06% |
| KFRC | 45.38% | $1.10B | -8.71% | 0.66% |
| HCKT | 44.40% | $838.57M | +36.65% | 1.45% |
| CRSP | 44.40% | $4.01B | -30.49% | 0.00% |
| FFIV | 44.29% | $13.97B | +44.43% | 0.00% |
| KN | 43.97% | $1.60B | +12.19% | 0.00% |
| CLNE | 43.92% | $589.93M | -23.92% | 0.00% |
| THRM | 43.33% | $1.28B | -10.01% | 0.00% |
| RGEN | 43.09% | $7.20B | -18.16% | 0.00% |
| FISI | 42.92% | $408.52M | +49.41% | 4.56% |
| AAT | 42.65% | $1.70B | +49.52% | 4.83% |
| AZTA | 42.51% | $2.00B | -28.24% | 0.00% |
| GMRE | 42.41% | $579.18M | -10.99% | 9.69% |
| FBMS | 42.00% | $1.12B | +38.46% | 2.78% |
| TRST | 41.95% | $691.41M | +34.26% | 3.98% |
| CNOB | 41.91% | $1.03B | +41.32% | 2.65% |
| KAR | 41.88% | $2.09B | +31.90% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CNA | 0.08% | $13.16B | +23.03% | 3.61% |
| ECL | 0.30% | $69.18B | +30.92% | 0.93% |
| MNR | -0.35% | $1.66B | -10.71% | 15.90% |
| VSTA | -0.36% | $204.94M | -39.33% | 0.00% |
| AQB | -0.37% | $3.78M | -37.77% | 0.00% |
| NINE | 0.37% | $49.99M | -42.44% | 0.00% |
| NEUE | -0.40% | $40.93M | -34.13% | 0.00% |
| CL | -0.43% | $76.48B | +22.25% | 2.12% |
| RLMD | -0.55% | $89.92M | +1.36% | 0.00% |
| LPTH | 0.55% | $62.27M | +33.05% | 0.00% |
| ZTO | 0.56% | $12.58B | -4.71% | 4.73% |
| WMT | 0.56% | $696.11B | +66.69% | 1.38% |
| SAVA | 0.60% | $1.35B | +25.50% | 0.00% |
| EG | 0.76% | $15.92B | -8.98% | 2.02% |
| LU | -0.87% | $2.01B | -33.75% | 0.00% |
| GCT | 0.91% | $983.16M | +147.95% | 0.00% |
| ALTO | 0.96% | $106.54M | -39.83% | 0.00% |
| X | -0.97% | $8.76B | +13.32% | 0.51% |
| OCX | 1.03% | $42.93M | -36.09% | 0.00% |
| KSPI | 1.04% | $20.86B | +18.06% | 3.37% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -21.35% | $78.15B | +35.51% | 0.42% |
| MRK | -16.17% | $244.21B | -5.55% | 3.18% |
| STG | -11.23% | $35.67M | +7.92% | 0.00% |
| PGR | -10.30% | $149.10B | +57.29% | 0.45% |
| CBOE | -10.26% | $21.46B | +15.84% | 1.11% |
| HUSA | -9.64% | $16.69M | -11.56% | 0.00% |
| PG | -9.40% | $402.15B | +14.14% | 2.33% |
| CHD | -8.58% | $27.18B | +19.50% | 1.03% |
| QXO | -8.38% | $6.51B | -35.95% | 0.00% |
| TCTM | -7.63% | $8.10M | -42.99% | 0.00% |
| OXBR | -7.15% | $19.05M | +178.18% | 0.00% |
| CME | -7.08% | $82.76B | +9.21% | 1.98% |
| WWD | -6.94% | $10.19B | +29.97% | 0.44% |
| GAN | -6.68% | $83.39M | +21.19% | 0.00% |
| CYD | -6.65% | $364.46M | -2.94% | 4.26% |
| LDOS | -6.56% | $21.12B | +49.80% | 0.96% |
| PANW | -5.94% | $126.99B | +46.98% | 0.00% |
| CIG.C | -5.58% | $2.48B | -3.55% | 0.00% |
| CCEC | -5.44% | $1.02B | +28.03% | 3.26% |
| NTZ | -4.80% | $47.64M | -30.94% | 0.00% |
ETF's related to NEO
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IWM | 53.42% | $75.73B | 0.19% |
| VTWO | 53.39% | $12.38B | 0.1% |
| SPSM | 53.28% | $12.72B | 0.03% |
| IJR | 53.19% | $90.05B | 0.06% |
| PRFZ | 53.11% | $2.65B | 0.39% |
| NUSC | 53.08% | $1.27B | 0.31% |
| GSSC | 52.97% | $529.86M | 0.2% |
| ESML | 52.92% | $1.90B | 0.17% |
| SLYG | 52.87% | $3.69B | 0.15% |
| IWN | 52.86% | $13.17B | 0.24% |
| IJT | 52.65% | $6.64B | 0.18% |
| CALF | 52.63% | $8.93B | 0.59% |
| FYX | 52.47% | $959.00M | 0.6% |
| IJS | 52.46% | $7.37B | 0.18% |
| EES | 52.34% | $668.71M | 0.38% |
| VIOV | 52.28% | $1.44B | 0.15% |
| XHE | 52.17% | $213.41M | 0.35% |
| SMMD | 52.13% | $1.24B | 0.15% |
| SLYV | 52.07% | $4.16B | 0.15% |
| VIOO | 52.03% | $3.12B | 0.1% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -40.34% | $388.04M | 1.43% |
| USDU | -31.19% | $201.97M | 0.5% |
| UUP | -28.57% | $309.25M | 0.77% |
| VIXY | -23.90% | $195.31M | 0.85% |
| CTA | -10.37% | $350.27M | 0.78% |
| WEAT | -10.30% | $120.27M | 0.28% |
| EQLS | -10.09% | $76.08M | 1% |
| TAIL | -9.42% | $67.98M | 0.59% |
| CORN | -9.04% | $61.12M | 0.2% |
| KMLM | -8.90% | $353.87M | 0.9% |
| JUCY | -8.79% | $324.29M | 0.6% |
| SGOV | -8.23% | $27.53B | 0.09% |
| KCCA | -6.33% | $220.51M | 0.87% |
| HIGH | -5.98% | $302.78M | 0.51% |
| DBA | -5.24% | $755.88M | 0.93% |
| TBIL | -2.46% | $4.38B | 0.15% |
| MINT | -2.11% | $11.62B | 0.35% |
| XHLF | -1.92% | $874.27M | 0.03% |
| AGZD | -1.69% | $142.76M | 0.23% |
| SOYB | -1.20% | $27.32M | 0.22% |
News
Finnhub
Ownership Submission FORM 4 Check this box if no longer...
Yahoo
FT. MYERS, Fla., November 19, 2024--NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 (booth #830).
Yahoo
FORT MYERS, Fla., November 14, 2024--NeoGenomics announced the appointment of Felicia Williams to its Board of Directors.
Finnhub
FT. MYERS - NeoGenomics, Inc. , a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference.Members of the management team will participate in an...
Yahoo
NeoGenomics ( NASDAQ:NEO ) Third Quarter 2024 Results Key Financial Results Revenue: US$167.8m (up 10% from 3Q 2023...
Yahoo
Q3 2024 Neogenomics Inc Earnings Call
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.